Inici › Limfoma de Burkitt › Texas › Houston
Assaigs clínics de Limfoma de Burkitt a Houston, TX
21 estudis de Limfoma de Burkitt busquen participants en centres de Houston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
ReclutantFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
ReclutantFase 3
- Houston Methodist Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutantEstudi observacional
- Texas Children's Hospital, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
ReclutantFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutantFase 3
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
ReclutantFase 3
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
ReclutantFase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
ReclutantFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
ReclutantFase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
ReclutantFase 2
- Baylor Texas Children's Hospital, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
ReclutantFase 1/2
- Research Site, Houston
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
ReclutantFase 2
- M D Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ReclutantFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
ReclutantFase 1/2
- M D Anderson Cancer Center, Houston
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
ReclutantFase 1/2
- Research Site, Houston
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
ReclutantFase 2
- M D Anderson Cancer Center, Houston
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
ReclutantFase 1
- University of Texas MD Anderson Cancer Center, Houston
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
ReclutantFase 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Assaigs de Limfoma de Burkitt en altres ciutats
- Milwaukee, WI16 estudis
- Philadelphia, PA16 estudis
- New York City, NY14 estudis
- Chicago, IL14 estudis
- Cincinnati, OH12 estudis
- Atlanta, GA12 estudis
- Seattle, WA11 estudis
- Boston, MA10 estudis
- Durham, NC10 estudis
- Aurora, CO10 estudis
- Los Angeles, CA10 estudis
- Kansas City, MO10 estudis
Altres estudis a Houston
- Càncer de pulmó de cèl·lules no petites145 estudis
- Càncer de mama126 estudis
- Càncer (tots els tipus)121 estudis
- Càncer metastàtic104 estudis
- Càncer colorrectal102 estudis
- Càncer d'ovari89 estudis
- Leucèmia mieloide aguda85 estudis
- Càncer de pulmó78 estudis
- Càncer de pròstata76 estudis
- Càncer d'endometri68 estudis
- Càncer de pàncrees61 estudis
- Melanoma59 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.